Semaglutide

Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic®/Wegovy® and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio

Retrieved on: 
Wednesday, February 28, 2024

NPM-119 has previously demonstrated pharmacokinetic data exhibiting continuous and therapeutic exenatide exposure levels over a six-month duration in healthy rats.

Key Points: 
  • NPM-119 has previously demonstrated pharmacokinetic data exhibiting continuous and therapeutic exenatide exposure levels over a six-month duration in healthy rats.
  • These preclinical data provide further evidence that the weight loss potential of exenatide treatment in humans may be comparable to other GLP-1 molecules such as semaglutide assuming adequate exposure levels are achieved and maintained.
  • NPM-115 is planned to maximize exenatide’s weight loss effect in humans, pending further development and regulatory clearance, by evaluating exenatide exposure levels higher than previously explored.
  • Dr. Mendelsohn will present study results on May 17 at the TIDES USA 2024 conference in Boston.

Virta Health Announces First-of-its-Kind Peer-Reviewed Study Proving Its Approach Is an Effective Off-Ramp From GLP-1s for Sustained Weight Loss

Retrieved on: 
Thursday, February 29, 2024

(Graphic: Business Wire)

Key Points: 
  • (Graphic: Business Wire)
    These outcomes stand in stark contrast to other real-world results of GLP-1 weight loss treatments.
  • At one year follow-up, both groups achieved significant and sustained improvement in weight loss, with no differences between the groups.
  • In line with these new findings, Virta announced the expansion of its Sustainable Weight Loss solution, a comprehensive approach to weight loss that enables employers and payers to offer responsible and individualized use of GLP-1s.
  • Members can achieve clinical weight loss without the use of medications, or with medications in combination with Virta’s personalized nutrition therapy.

Every Cure to Receive $48.3M from ARPA-H to Develop AI-Driven Platform to Revolutionize Future of Drug Development and Repurposing

Retrieved on: 
Wednesday, February 28, 2024

NEW YORK, Feb. 28, 2024 /PRNewswire/ -- Every Cure, a nonprofit on a mission to save lives by repurposing existing medicines, announced today significant funding from the Advanced Research Projects Agency for Health (ARPA-H). The three-year, $48.3 million contract was unveiled at the White House this evening and represents a substantial federal investment in drug repurposing. It will accelerate Every Cure's mission to unlock the full potential of existing drugs to treat more diseases through the development of an AI-powered platform, called ML/AI-enabled Therapeutic Repurposing In eXtended uses (MATRIX).

Key Points: 
  • The three-year, $48.3 million contract was unveiled at the White House this evening and represents a substantial federal investment in drug repurposing.
  • "I'm alive and in remission from my rare disease thanks to a repurposed drug that I discovered.
  • "Through Every Cure, we are working tirelessly to unlock the full potential of FDA-approved drugs to treat many more diseases.
  • The ARPA-H funding will enable Every Cure to:
    Develop an open-source drug repurposing database.

Vizient Projects 3.8% Drug Price Increase Driven by Specialty Pharmaceuticals

Retrieved on: 
Tuesday, January 30, 2024

Vizient, Inc. projects drug price inflation to grow at 3.8% in the latest Pharmacy Market Outlook.

Key Points: 
  • Vizient, Inc. projects drug price inflation to grow at 3.8% in the latest Pharmacy Market Outlook.
  • Driven in part by specialty pharmacy, including the increasing utilization of weight loss drugs, it is the highest projected increase since July 2019.
  • “Many hospitals around the country experienced a challenging 2023, including drug shortages and rising drug costs,” said Carina Dolan, associate vice president, clinical oncology, pharmacoeconomics and market insights, Vizient.
  • With 42 novel specialty drugs approved in 2023 — and 2024 likely to see a record number of approvals — the projected price increase for specialty medications is 4.18%.

OrderlyMeds Unveils Innovative Injectable and Oral Semaglutide for Breakthrough Weight-Loss Management in Atlanta

Retrieved on: 
Tuesday, January 30, 2024

Semaglutide, a cutting-edge GLP-1 medication with proven efficacy in weight management, is now available in two convenient formats through OrderlyMeds: Injectable Semaglutide and Oral Semaglutide.

Key Points: 
  • Semaglutide, a cutting-edge GLP-1 medication with proven efficacy in weight management, is now available in two convenient formats through OrderlyMeds: Injectable Semaglutide and Oral Semaglutide.
  • Key Features of OrderlyMeds' Weight-Loss Management Program:
    Dual Delivery Options: Choose between Injectable Semaglutide and Oral Semaglutide based on personal preferences and lifestyle.
  • "OrderlyMeds is thrilled to bring our innovative weight-loss management program to the vibrant city of Atlanta," said Chris Spears, CEO at OrderlyMeds.
  • OrderlyMeds' Weight-Loss Management Program is now available nationwide and is based in Atlanta, and interested individuals can learn more by visiting www.orderlymeds.com

Sustainable Weight Loss with GLP-1's and bistroMD

Retrieved on: 
Wednesday, January 17, 2024

NAPLES, Fla., Jan. 17, 2024 /PRNewswire/ -- Glucagon-Like Peptide-1 (GLP-1's) are medications that manage blood sugar levels for people with type-2 diabetes. Ozempic, a type of GLP-1, has been making headlines as a miracle drug for fast weight loss. While GLP-1's can be used for rapid weight loss; healthy, sustainable weight loss can only be achieved through dietary modification and proper nutrition. Changing engrained eating habits is hard, but bistroMD, a doctor-designed meal delivery service, provides support to GLP-1 users. 

Key Points: 
  • Ozempic, a type of GLP-1, has been making headlines as a miracle drug for fast weight loss.
  • While GLP-1's can be used for rapid weight loss; healthy, sustainable weight loss can only be achieved through dietary modification and proper nutrition.
  • Ultimately, while GLP-1's can be great short-term solutions to jumpstarting weight loss, their high cost prohibits long-term access for most.
  • If GLP-1's are not accompanied by proper nutrition and sustainable eating habits, the unhealthy pattern of weight cycling will continue.

Victory Square Portfolio Company Hydreight Provides Year-End Review on Significant Growth and Progress

Retrieved on: 
Tuesday, January 9, 2024

The Company achieved many significant accomplishments throughout the year across all aspects of the business.

Key Points: 
  • The Company achieved many significant accomplishments throughout the year across all aspects of the business.
  • Invested significantly in proprietary technology platform and legal framework to adhere to the complex healthcare regulations in the United States.
  • Provided almost 40,000 services to patients, compared to 15,600 services in 2022, representing an increase of over 150%.
  • Filled 8,786 in total pharmacy orders during the year, compared to 3,021 total orders in 2022, representing an increase of 191%.

Hydreight Provides Year-End Review on Significant Growth and Progress

Retrieved on: 
Monday, January 8, 2024

The Company achieved many significant accomplishments throughout the year across all aspects of the business.

Key Points: 
  • The Company achieved many significant accomplishments throughout the year across all aspects of the business.
  • Filled 8,786 in total pharmacy orders during the year, compared to 3,021 total orders in 2022, representing an increase of 191%.
  • Shane Madden, CEO of Hydreight commented, “We are building one of the largest mobile clinical network in the United States and 2023 was a transformative year with significant growth across the entire business.
  • On behalf of the Hydreight team, we would like to wish everyone a Happy New Year!”

CES 2024: AI-Powered Weight Loss Takes Center Stage as EW2Health Unveils Game-Changing Sinque Technology

Retrieved on: 
Friday, January 5, 2024

THE HAGUE, Netherlands, Jan. 5, 2024 /PRNewswire-PRWeb/ -- EW2Health (Easy Way to Health), a technology company developing innovative, friendly, data-driven solutions for health professionals, today announced plans to showcase Sinque™, its patented behavioral analytics and monitoring solution for weight loss, at CES 2024. EW2Health will demonstrate Sinque as part of the NL Tech Pavilion in Eureka Park, Booth 62100 at the Venetian Expo, from January 9–12, 2024. Additionally, EW2Health will pitch on the CES Startup Stage on Wednesday, January 10, 2–4 p.m., after winning one of the eight coveted pitch spots among more than 50 competing startups. Watch this short video to learn more about Sinque.

Key Points: 
  • EW2Health will demonstrate Sinque as part of the NL Tech Pavilion in Eureka Park, Booth 62100 at the Venetian Expo, from January 9–12, 2024.
  • Sinque benefits weight loss professionals, corporate wellness, health insurance, preventive medicine, and health innovators.
  • The Sinque patented algorithm uses predictive behavioral analytics to learn a user's weight fluctuation patterns and predict their 'true' weight trend.
  • Health professionals use the Sinque technology dashboard to assess individual and group metrics and to gauge adherence, weight trends and weight loss results.

Virta Expands its Provider-led Weight Loss Program to Adults with BMI >25 As Demand Surges for Cost Effective Alternatives to GLP-1 Drugs

Retrieved on: 
Thursday, January 4, 2024

Virta Health, the leader in drug-free clinical weight loss and type 2 diabetes reversal, today announced significant traction against the company’s expansion into weight loss solutions.

Key Points: 
  • Virta Health, the leader in drug-free clinical weight loss and type 2 diabetes reversal, today announced significant traction against the company’s expansion into weight loss solutions.
  • “Virta delivers drug-like impact, without the drugs,” said Dr. Adam Wolfberg, Chief Medical Officer at Virta.
  • For nearly a decade, Virta Health has been de-prescribing GLP-1 drugs while sustaining clinically significant weight loss.
  • Because much of the weight loss is regained once people stop using the drugs, much of the spend on GLP-1s is also therefore wasted.